Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Insight - Paving the way for M&A

This article was originally published in Scrip

Executive Summary

One of the foremost critical thoughts in preparing for a merger or acquisition is the management of confidential information. Since the lifeblood of any biotechnology company is its IP, great care must be taken to ensure that confidential information is not prematurely disclosed. Accordingly, in the early stages of discussions it is important to ensure that only information that is in the public domain is revealed. Indeed, it may be damaging for a company to reveal that it is even thinking of being sold, as that might be only one of the options under consideration. In those circumstances, a third party can be used to send out non-confidential information on a no-names basis. Once the time has come to provide confidential information, the company will require any prospective purchasers to sign a non-disclosure agreement (NDA) under which the prospective purchasers agree not to disclose any confidential information that the company provides in relation to the proposed sale. Even with an NDA in place, vendors may wish to hold back key information until after it has received an offer from a prospective purchaser.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts